TCBP
TC BioPharmTCBP
TCBP
About: TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
Employees: 41
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
50% more funds holding
Funds holding: 8 [Q3] → 12 (+4) [Q4]
0% less ownership
Funds ownership: 0.01% [Q3] → 0% (-0%) [Q4]
29% less capital invested
Capital invested by funds: $48.9K [Q3] → $34.8K (-$14K) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for TCBP.
Financial journalist opinion
Based on 4 articles about TCBP published over the past 30 days
Neutral
PRNewsWire
1 week ago
TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
FDA-approved product in a multi-billion-dollar market Revenue generation projected in 2025 EDINBURGH, Scotland , March 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the execution of a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company focused on commercializing novel therapies for decreasing intraocular pressure in patients with glaucoma and ocular hypertension. The acquisition candidate has an FDA-approved once-per-day drop to decrease intraocular pressure, a pipeline of development stage assets in ophthalmology indications, and is led by a seasoned management team.
Neutral
PRNewsWire
2 weeks ago
TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
EDINBURGH, Scotland , Feb. 20, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) , a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its CEO will join the Cancer Progress Panel discussion on February 27 th at 1:10 pm CET at the 18th Annual European Life Sciences CEO Forum, which will include HealthTech topics such as AI, convergence, and diagnostics. The forum will take place on the 26th - 27th of February 2025 at the Hilton Zurich Airport Hotel.
Neutral
PRNewsWire
3 weeks ago
TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
No adverse events related to TCB008 have occurred Evidence of stable disease following TCB008 infusion EDINBURGH, Scotland , Feb. 13, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it has concluded dosing of Cohort A patients in the ACHIEVE Phase 2B UK clinical trial. The available data show a favorable safety and efficacy response in Cohort A patients, patients with relapse or refractory AML.
Neutral
PRNewsWire
4 weeks ago
TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
First Cohort B patient received 4 doses (approx. 819 million Gamma Delta T-cells) Cohort B recruitment continues at multiple clinical sites across the United Kingdom EDINBURGH, Scotland , Feb. 10, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the first Cohort B patient in the ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 in Acute Myeloid Leukemia, has completed the full dosing regiment.
Neutral
PRNewsWire
1 month ago
TCBP to Implement ADS Ratio Change
EDINBURGH, Scotland , Feb. 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it will change its ratio of its American Depositary Shares ("ADSs") to ordinary shares from one (1) ADS representing two hundred (200) ordinary shares to one ADS representing four thousand (4,000) ordinary shares (the "ADS Ratio Change"). The ADS Ratio Change is expected to become effective on February 10, 2025, U.S. Eastern Time.
Neutral
PRNewsWire
1 month ago
TCBP Announces H5N1 Proof of Concept Studies Intention
EDINBURGH, Scotland , Jan. 15, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB008, for treatment in H5N1, commonly known as "Bird Flu." The Company is currently approaching potential university partners to expedite the preclinical work required for a Phase I study.
Neutral
PRNewsWire
1 month ago
TCBP to Present at Sequire Investor Summit 2025
EDINBURGH, Scotland , Jan. 13, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that CEO Bryan Kobel will be presenting a corporate overview at the upcoming Sequire Investor Summit 2025. The conference is scheduled for January 21-23, 2025, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico.
Neutral
PRNewsWire
2 months ago
TCBP Trading Continues Unabated on Nasdaq Stock Exchange
EDINBURGH, Scotland , Jan. 6, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that its American Depository Shares (ADSs) has continued trading on the Nasdaq Global Select Market (Nasdaq) under the ticker symbol 'TCBP'. There has been no halt in trading and shares are expected to continue trading unabated.
Neutral
PRNewsWire
2 months ago
TCBP Provides Update on Acquisition Strategy and Current Targets
EDINBURGH, Scotland , Dec. 31, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T-cell therapies for cancer and other indications, today announced it has advanced negotiations with both of its previously aforementioned acquisition candidates. This past spring TCBP announced the execution of non-binding letters of intent as part of its M&A strategy aimed at expanding its therapeutic platform.
Neutral
PRNewsWire
2 months ago
TCBP Issues 25% Stock Dividend
EDINBURGH, Scotland , Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that shareholders have formally approved the recently announced 25% stock dividend. Today, TC BioPharm declared that last week's proposed special stock dividend was formally approved at today's General Meeting of the Company.
Charts implemented using Lightweight Charts™